DE1253488B - Serologisches Reagenz fuer Schwangerschaftsteste in vitro und Methode zu seiner Herstellung - Google Patents
Serologisches Reagenz fuer Schwangerschaftsteste in vitro und Methode zu seiner HerstellungInfo
- Publication number
- DE1253488B DE1253488B DE1961B0063045 DEB0063045A DE1253488B DE 1253488 B DE1253488 B DE 1253488B DE 1961B0063045 DE1961B0063045 DE 1961B0063045 DE B0063045 A DEB0063045 A DE B0063045A DE 1253488 B DE1253488 B DE 1253488B
- Authority
- DE
- Germany
- Prior art keywords
- hcg
- serum
- antiserum
- antigen
- complement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims description 22
- 239000003153 chemical reaction reagent Substances 0.000 title claims description 12
- 238000000338 in vitro Methods 0.000 title claims description 6
- 238000009597 pregnancy test Methods 0.000 title claims description 6
- 238000000034 method Methods 0.000 title description 21
- 230000000405 serological effect Effects 0.000 title description 11
- 210000002966 serum Anatomy 0.000 claims description 50
- 238000002347 injection Methods 0.000 claims description 10
- 239000007924 injection Substances 0.000 claims description 10
- 230000001900 immune effect Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 description 35
- 102000036639 antigens Human genes 0.000 description 35
- 108091007433 antigens Proteins 0.000 description 35
- 230000000295 complement effect Effects 0.000 description 32
- 238000006243 chemical reaction Methods 0.000 description 24
- 238000010790 dilution Methods 0.000 description 23
- 239000012895 dilution Substances 0.000 description 23
- 238000012360 testing method Methods 0.000 description 22
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 19
- 229940088597 hormone Drugs 0.000 description 16
- 239000005556 hormone Substances 0.000 description 15
- 238000004448 titration Methods 0.000 description 15
- 210000002700 urine Anatomy 0.000 description 15
- 239000002671 adjuvant Substances 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 206010018910 Haemolysis Diseases 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 230000008588 hemolysis Effects 0.000 description 12
- 230000035935 pregnancy Effects 0.000 description 12
- 241000283973 Oryctolagus cuniculus Species 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 9
- 229960002319 barbital Drugs 0.000 description 9
- 238000011081 inoculation Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 210000001124 body fluid Anatomy 0.000 description 8
- 239000010839 body fluid Substances 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 235000002639 sodium chloride Nutrition 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 239000013589 supplement Substances 0.000 description 4
- JDRAOGVAQOVDEB-KTKRTIGZSA-N (3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl) (z)-octadec-9-enoate Chemical compound OC1COC2C(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC21 JDRAOGVAQOVDEB-KTKRTIGZSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 108010086677 Gonadotropins Proteins 0.000 description 3
- 102000006771 Gonadotropins Human genes 0.000 description 3
- 239000005662 Paraffin oil Substances 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000002391 anti-complement effect Effects 0.000 description 3
- 238000010170 biological method Methods 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000002622 gonadotropin Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000186359 Mycobacterium Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003171 anti-complementary effect Effects 0.000 description 2
- 238000012754 cardiac puncture Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010003021 Gestyl Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- LUXUAZKGQZPOBZ-SAXJAHGMSA-N [(3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O LUXUAZKGQZPOBZ-SAXJAHGMSA-N 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000003115 checkerboard titration Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000001456 gonadotroph Effects 0.000 description 1
- 229940094892 gonadotropins Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 239000012875 nonionic emulsifier Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229940045662 porcine thyroid Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- RGHFKWPGWBFQLN-UHFFFAOYSA-M sodium;5,5-diethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC1(CC)C([O-])=NC(=O)NC1=O RGHFKWPGWBFQLN-UHFFFAOYSA-M 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/76—Human chorionic gonadotropin including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Reproductive Health (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2261060A GB994631A (en) | 1960-06-28 | 1960-06-28 | Antisera for determining pregnancy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE1253488B true DE1253488B (de) | 1967-11-02 |
Family
ID=10182231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE1961B0063045 Pending DE1253488B (de) | 1960-06-28 | 1961-06-27 | Serologisches Reagenz fuer Schwangerschaftsteste in vitro und Methode zu seiner Herstellung |
Country Status (7)
| Country | Link |
|---|---|
| BE (1) | BE605517A (en, 2012) |
| BR (1) | BR6130413D0 (en, 2012) |
| CH (1) | CH431818A (en, 2012) |
| DE (1) | DE1253488B (en, 2012) |
| DK (1) | DK103212C (en, 2012) |
| GB (1) | GB994631A (en, 2012) |
| NL (1) | NL266403A (en, 2012) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4003988A (en) * | 1976-06-01 | 1977-01-18 | Warner-Lambert Company | Direct agglutination test for pregnancy |
-
0
- NL NL266403D patent/NL266403A/xx unknown
- BE BE605517D patent/BE605517A/xx unknown
-
1960
- 1960-06-28 GB GB2261060A patent/GB994631A/en not_active Expired
-
1961
- 1961-06-23 DK DK257161A patent/DK103212C/da active
- 1961-06-23 CH CH741761A patent/CH431818A/de unknown
- 1961-06-27 DE DE1961B0063045 patent/DE1253488B/de active Pending
- 1961-06-28 BR BR13041361A patent/BR6130413D0/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BE605517A (en, 2012) | |
| GB994631A (en) | 1965-06-10 |
| NL266403A (en, 2012) | |
| DK103212C (da) | 1965-11-29 |
| CH431818A (de) | 1967-03-15 |
| BR6130413D0 (pt) | 1973-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2518546A1 (de) | Kontrazeptiver impfstoff | |
| DE2128670A1 (de) | Immunologische Isoenzym Bestimmungs methode | |
| DE2548963A1 (de) | Verfahren und mittel zur bestimmung der aktivitaet von creatinkinase-mb | |
| DE1598832A1 (de) | Auf der Beobachtung eines Agglutinationsvorganges beruhendes Verfahren zum Nachweis von Choriongonadotropin in Koerperfluessigkeiten | |
| DE2602997C2 (de) | Lyophilisierte Kollagenzubereitung und Verfahren zu ihrer Herstellung | |
| DE3105555C2 (en, 2012) | ||
| DE2403994A1 (de) | Herstellung von antisera | |
| DE69228061T2 (de) | Sulfatierte glykolipide, die eine galaktose-3-0-sulfate-gruppierung enthalten, und spezifische fänger für diese für die verwendung in der prophylaxe oder therapie der prädiabetis, diabetis und/oder damit zusammenhängender komplikationen in einem individuum | |
| DE69015230T2 (de) | Antikörper gegen menschliches Sperma, ihre Herstellung und Anwendung. | |
| DE2421943A1 (de) | Modifizierte polypeptide | |
| DE2025718C3 (de) | Verfahren zum Stabilisieren von lyophillsierten Erythrozyten | |
| CH652032A5 (de) | Verfahren zur herstellung von immunbiologischen praeparaten, die fuer den nachweis, das vorbeugen und/oder die behandlung der candida guilliermondii-infektion geeignet sind. | |
| DE1253488B (de) | Serologisches Reagenz fuer Schwangerschaftsteste in vitro und Methode zu seiner Herstellung | |
| DE2854723C3 (de) | Hetero-Impfstoff zur therapeutischen Behandlung des Trichomonas -Syndroms und Verfahren zu seiner Herstellung | |
| Brody et al. | Studies on the Determination of Human Chorionic Gonadotrophs by Complement Fixation | |
| DE2555188C2 (de) | Verfahren zum Nachweis von Antigen oder Antikörper von infektiöser Hepatitis A in einer Probe | |
| AT233170B (de) | Serodiagnostisches Reagens und Verfahren zu seiner Herstellung | |
| Brambell et al. | The accumulation of antibodies in the stomach contents of foetal rabbits | |
| DE4103727A1 (de) | Zur spezifischen erkennung eines antigens des stratum corneum der menschlichen epidermis befaehigte antikoerper, ihre herstellung und ihre anwendung, insbesondere als traeger von arzneimittelwirkstoffen | |
| DE2728802C2 (de) | Verfahren zum Herstellen eines antischistosomen immunologischen Mittels | |
| DE2440926B2 (de) | lnjizierbarer 'inaktivierter Impfstoff gegen Hepatitis B und Verfahren zu seiner Herstellung | |
| DE1954728A1 (de) | Blutagglutination-Inhibierungstest fuer Viren | |
| DE2334344A1 (de) | Antiserum fuer radioimmuntests, verfahren zur gewinnung desselben sowie radioimmunologisches verfahren | |
| DE2035784A1 (en) | Tubes part-filled with antigens - in gel for antigen-antibody reaction in body fluids visible as a narrow precipitation zone | |
| DE2551431A1 (de) | Anti-embryoserum und schwangerschafts- bzw. traechtigkeits-diagnoseverfahren |